The adjuvant therapies in melanoma are given when a patient is clinically free of disease after surgical treatment of the primary high risk-tumor. The interferon adjuvant therapy is intended to prolong overall survival in melanoma patients, according to the journal which is issued on November, 2007 at Alberta Cancer Board guideline. According to the Guideline, patients with in-situ less than 2 mm thick, 2 – 4 mm thick but non-ulcerated or…
Advertisement
Find Your Job
Health Job Site




